pCPA Update as of October 31, 2017

November 8, 2017
-

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

 

The October 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:

  • Two new drug products have initiated pCPA negotiations, for a total of 46 active negotiations;
  • Seven negotiations have been completed/closed, for a total of 177 joint completed/closed negotiations; and
  • No new drug products were added to the “No pCPA Negotiations” list, for a total of 55 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.
  • No new drug products were added to the “Negotiations considered by each province/territory” list for a total of 13 drug products that were individually considered at the provincial-territorial level.

In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since September 30, 2017 is as follows:

  • Three new drug products have received recent CDEC or pERC recommendations, for a total of approximately 18 products under pCPA Consideration

Please see below for more details.

  • Two new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations
Brand Name
Generic Name
Manufacturer
Indication
Recommendation/
Notification to Implement Date
Time to Negotiation* (days)
Gazyva
obinutuzumab Hoffmann-La Roche Ltd. Follicular Lymphoma June 19, 2017 118 days
Lynparza (resubmission)
olaparib AstraZeneca Canada Inc. Ovarian Cancer October 5, 2017 10 days

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation

  • Seven negotiations have been completed/closed since the last update, for a total of 177 joint completed/closed negotiations.
    • Four negotiations were completed:
Brand Name
Generic Name
Manufacturer
Indication
Negotiation Initiation
Duration * (days)
Erelzi
Etanercept Sandoz Canada Inc. Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis and rheumatoid arthritis April, 2017 183 days
Humira
Adalimumab AbbVie Corporation Hidradenitis suppurativa July, 2017 92 days
Prolia
Denosumab Amgen Canada osteoporosis December, 2015 670 days
Repatha
Evolocumab Amgen Canada Primary hyperlipidemia and mixed dyslipidemia July, 2016 457 days
    • Three negotiations were closed:
Brand Name
Generic Name
Manufacturer
Indication
Negotiation Initiation
Duration * (days)
Invokamet
Canagliflozin/metformin/

hydrochloride

Janssen Inc. Type 2 Diabetes May, 2017 153 days
Kalydeco
ivacaftor Vertex Pharmaceuticals Canada Cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation January, 2015 1,004 days
Kevzara
Sarilumab Sanofi Genzyme Rheumatoid Arthritis July, 2017 92 days

*Approximation: Negotiation initiation and end date assumed to be mid-month for the purposes of the calculation

Based on information collected by MORSE Consulting:

  • Three new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 18 products under pCPA Consideration.
Brand Name
Generic Name
Manufacturer
Indication
Final Recommendation/Notification to Implement
Izba
travoprost ophthalmic solution Novartis Pharmaceuticals Canada Inc. open-angle glaucoma October 25, 2017
Dysport Therapeutic
abobotulinumtoxinA IPSEN Biopharmaceuticals Canada, Inc Upper limb spasticity October 24, 2017
Darzalex
Daratumumab Janssen Canada Inc. Multiple myeloma October 23, 2017

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share